Abstract: FR-PO1096
Usefulness of Multiplex Immunodot Method for COVID-19 Vaccination Monitoring in Dialysis Patients: Results of the COVIDIAL Study
Session Information
- COVID-19 - II
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Debelle, Frederic, Centre Hospitalier EpiCURA Baudour, Baudour, Hainaut , Belgium
- Gankam Kengne, Fabrice, Centre Hospitalier EpiCURA Ath, Ath, Hainaut , Belgium
- Guillen-Anaya, Miguel-Ange, Centre Hospitalier EpiCURA Hornu, Hornu, Hainaut , Belgium
- Decleves, Anne-Emilie, Universite de Mons, Mons, Walloon Region, Belgium
Group or Team Name
- CoviDial Study Group.
Background
COVID-19 vaccine was demonstrated to be effective in dialysis patients, but boosters are mandatory due to a rapid waning of anti-spike antibodies. A vaccination strategy based on efficient immunologic response monitoring might be useful to maintain a favourable risk-benefit balance in this vulnerable population.
Methods
CoviDial is an observational prospective study enrolling 121 dialysis patients to receive a 3-dose mRNA-1273 vaccine according to a uniform schedule. At baseline, months 1, 3, 6, 9, and 12, anti-spike antibodies against four epitopes (S1, S2, ECD-S1+S2, RBD) were monitored with a multiplex immunodot enzymatic assay. Potential correlation between initial serologic response and subsequent COVID-19 infection was then assessed.
Results
Overall, 96.2% and 96.8% of patients developed anti-RBD antibodies at 3 and 12 months, respectively. All antibodies titres significantly decreased at month 6 compared to month 3. Booster vaccine induced a robust serologic response at month 9, but with a waning three months later, particularly for anti-S2 (37.2 ± 3.3 vs. 61.3 ± 3.0, p<0.0001) and anti-S1+S2 antibodies (68.4 ± 3.3 vs. 88.4 ± 2.3, p<0.01). Fifteen patients were later tested positive for SARS-CoV-2. At month 3, mean titres of anti-RBD, anti-S1+S2 and anti-S2 antibodies were lower in the subsequent SARS-CoV-2 infected cohort (71.57±9.01 vs. 85.79±2.61, p<0.05; 41.07±7.96 vs. 61.68±3.56, p<0.05; 13.79±5.03 vs. 39.70±3.86, p<0.01; respectively).
Conclusion
Three doses of mRNA-1273 vaccine induce a robust but time-limited immunologic response in dialysis patients. Lower anti-spike antibodies titres after initial vaccination are associated with a higher risk to subsequently contract SARS-CoV-2, even beyond six months.
Funding
- Private Foundation Support